Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
LT Inhibitor
Tryptanthrin is a potent inhibitor of leukotriene (LT) biosynthesis, targeting the inflammatory pathways involved in various diseases. This indole quinazoline compound exhibits significant anticancer properties by suppressing the expression of key inflammatory mediators such as NOS1, COX-2, and NF-κB. Additionally, Tryptanthrin modulates cytokine levels, influencing the expression of IL-2, IL-10, and TNF-α, making it a valuable reagent for research applications in inflammation and cancer biology. -
MAO-A/B Inhibitor
1,4-Naphthoquinone serves as a potent inhibitor targeting monoamine oxidase A and B (MAO-A/B) with competitive inhibition of MAO-B (Ki=1.4 μM) and non-competitive inhibition of MAO-A (Ki=7.7 μM). This compound exhibits broad-spectrum biological activity, inhibiting various DNA polymerases alongside notable anti-tumor, anti-inflammatory, and antibacterial properties. Its mechanism includes the induction of oxidative stress, glutathione (GSH) depletion, suppression of DNA synthesis, and blockage of NF-κB nuclear translocation. 1,4-Naphthoquinone is applicable in research involving melanoma and colon cancer cell growth, endothelial cell function, and models of lipopolysaccharide (LPS)-induced inflammation. -
p300 Histone Acetylatransferase Inhibitor
Curcumin, a natural phenolic compound, functions as a specific inhibitor of the p300/CREB-binding protein histone acetyltransferase. It effectively represses the acetylation of both histone and nonhistone proteins, thereby modulating chromatin transcription. Curcumin exhibits significant biological activities, including anti-inflammatory, antioxidant, antiproliferative, and antiangiogenic effects, while also inhibiting NF-κB and MAPKs. Additionally, it promotes stabilization of the Nrf2 protein through modification of Keap1 cysteines, making it valuable for research in diverse therapeutic contexts. -
HDAC6 Inhibitor
HDAC6-IN-71 is a selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 13.68 nM for HDAC6 and 443.12 nM for HDAC1. This compound effectively reduces nitric oxide production in mouse macrophages, with an IC50 of 2.31 μM. By inhibiting the HDAC6-NF-κB signaling pathway, HDAC6-IN-71 leads to decreased phosphorylation of IκB-α and IKK-α/β, and downregulates the expression of key inflammatory mediators such as COX-2 and iNOS. Its efficacy has been demonstrated in models of ulcerative colitis, highlighting its potential for therapeutic applications in inflammatory diseases. -
HDACs/NF-κB Dual Inhibitor
Homobutein is a natural chalcone that functions as a potent dual inhibitor of histone deacetylases (HDACs) and nuclear factor kappa B (NF-κB), exhibiting IC50 values of 190 μM and 38 μM, respectively. This compound also acts as a chelator for iron (II and III) cations and demonstrates a range of biological activities, including anticancer, anti-inflammatory, antiparasitic, and antioxidant effects. Homobutein is valuable for research applications involving cellular signaling pathways and the investigation of potential therapeutic strategies in cancer and inflammatory diseases. -
HDAC3 Inhibitor
HDAC3-IN-T247 is a potent and selective inhibitor of HDAC3 (histone deacetylase 3), demonstrating an IC50 of 0.24 µM. This compound selectively enhances the acetylation of NF-κB in HCT116 cells, making it valuable for studies in cancer and viral pathogenesis. HDAC3-IN-T247 exhibits significant anticancer properties by inhibiting the proliferation of cancer cells and can also activate HIV gene expression in latently infected cells, thus serving as a useful tool for investigations in oncology and HIV research. -
Ferroptosis Inhibitor
5-Hydroxy-6,7-dimethoxyflavone is a potent inhibitor of ferroptosis, acting primarily to mitigate H1N1 virus-induced cell death. This compound enhances the expression of SLC7A11 and GPX4, thereby providing protective effects against ferroptosis. Additionally, it reduces inflammatory responses and apoptosis by inhibiting the activation of NF-κB and p38 MAPK signaling pathways. 5-Hydroxy-6,7-dimethoxyflavone is valuable for research related to H1N1 influenza virus infection and ferroptosis regulation. -
NF-κB Inhibitor
Ginsenoside Rg6 is an NF-κB inhibitor that effectively attenuates TNF-α-induced NF-κB transcriptional activity, exhibiting an IC50 of 29.34 μM in HepG2 cells. In addition to its role in modulating NF-κB activity, Ginsenoside Rg6 demonstrates significant apoptotic effects, making it a valuable tool for research in inflammation and cancer biology. -
CXCR Inhibitor
Corydalmine, a CXCR inhibitor, demonstrates significant antifungal activity by inhibiting spore germination in various plant pathogenic and saprophytic fungi. Additionally, it serves as an oral analgesic agent, exhibiting potent analgesic effects. Corydalmine has been shown to alleviate Vincristine-induced neuropathic pain in murine models through the inhibition of the NF-κB-dependent CXCL1/CXCR2 signaling pathway, making it a valuable tool for pain research and therapeutic applications. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-3 is a dual inhibitor targeting CYP51 and PD-L1, exhibiting potent antifungal activity with IC50 values of 0.205 μM and 0.039 μM, respectively. This compound induces early apoptosis in fungal cells by reducing levels of intracellular IL-2, NLRP3, and NF-κBp65 proteins. Additionally, CYP51/PD-L1-IN-3 causes mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately resulting in fungal lysis and cell death. This compound serves as a valuable tool for research in fungal infections and immune modulation. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-2 is a quinazoline compound that functions as a dual inhibitor of CYP51 and PD-L1, exhibiting IC50 values of 0.263 μM and 0.017 μM, respectively. It displays notable antifungal activity by triggering early apoptosis in fungal cells, leading to significant reductions in intracellular IL-2, NLRP3, and NF-κBp65 protein levels. Additionally, CYP51/PD-L1-IN-2 induces mitochondrial damage and reactive oxygen species (ROS) accumulation, culminating in fungal lysis and subsequent cell death. This compound is valuable for research exploring antifungal mechanisms and cancer immunotherapy. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-1 is a dual inhibitor targeting both CYP51 and PD-L1, exhibiting an IC50 of 0.884 μM for CYP51 and 0.083 μM for PD-L1. This quinazoline compound demonstrates notable antifungal activity by inducing early apoptosis in fungal cells while significantly reducing intracellular levels of IL-2, NLRP3, and NF-κBp65. Additionally, CYP51/PD-L1-IN-1 contributes to mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately leading to fungal lysis and cell death. This compound is valuable for research focused on antifungal therapies and immune modulation. -
CXCR Inhibitor
Corydalmine hydrochloride is a potent CXCR inhibitor that demonstrates significant biological activity by inhibiting spore germination in certain plant pathogenic and saprophytic fungi. Additionally, it exhibits notable analgesic properties, effectively alleviating Vincristine-induced neuropathic pain in murine models. This effect is mediated through the inhibition of the NF-κB-dependent CXCL1/CXCR2 signaling pathway, highlighting its potential applications in pain management research and fungal inhibition studies. -
MDA-9/Syntenin Inhibitor
PDZ1i (113B7) is a selective inhibitor of MDA-9/Syntenin, targeting its PDZ1 domain. This compound effectively inhibits radiation-induced invasion of glioblastoma (GBM) cells and enhances their radiosensitivity by disrupting key signaling pathways, including Src/EphA2, EGFRvIII/FAK, and NF-κB. PDZ1i also decreases the secretion of invasion-related proteases such as MMP-2, MMP-9, and ADAM9. Its anti-tumor efficacy has been demonstrated in nude mice models with intracranial U1242-luc and GBM xenografts, making PDZ1i a valuable tool for researching glioblastoma, as well as breast and prostate cancers. -
PARP1 Inhibitor
DPQ hydrochloride is a potent and selective inhibitor of PARP-1 (poly(ADP-ribose) polymerase 1), effectively blocking PARP-1-mediated DNA damage repair and reducing NAD+/ATP consumption. This compound demonstrates significant anti-inflammatory properties by inhibiting the activation of the NF-κB pathway, leading to a decrease in pro-inflammatory cytokines such as TNF-α and IL-6, as well as mitigating oxidative stress. DPQ hydrochloride is ideal for research applications related to inflammation and can be utilized in studies of conditions such as acute lung injury, myocardial infarction, and neurodegenerative diseases. -
PARP-1 Inhibitor
DPQ is a selective inhibitor of PARP-1, effectively blocking PARP-1-mediated DNA repair mechanisms and reducing the consumption of NAD+ and ATP. This inhibition leads to a decrease in NF-κB pathway activation, resulting in lowered expression of pro-inflammatory cytokines such as TNF-α and IL-6, along with a reduction in oxidative stress levels. DPQ is applicable in research focused on inflammation-related conditions including acute lung injury, myocardial infarction, and neurodegenerative diseases. -
C/EBPβ Inhibitor
Helenalin acetate is a potent C/EBPβ inhibitor that also functions as a natural NF-κB inhibitor. It exhibits significant anti-inflammatory and anticancer properties, making it a valuable tool for research into inflammatory diseases and cancer biology. This compound can be utilized in studies aimed at understanding the regulation of gene expression mediated by C/EBPβ and its role in various pathological conditions. -
COX-1/cAMP Phosphodiesterase Inhibitor
Triflusal is a dual inhibitor of Cyclooxygenase-1 (COX-1) and cAMP phosphodiesterase, which penetrates the blood-brain barrier. It effectively inhibits platelet aggregation, nuclear factor kappa B (NF-κB) activation, inducible nitric oxide synthase (iNOS) activity, and prostaglandin synthesis in ischemic tissues. Additionally, Triflusal enhances neutrophil nitric oxide production, endothelial nitric oxide synthase (eNOS) expression, and constitutive nitric oxide synthase (cNOS) activity. This compound is valuable for investigating thromboembolic and ischemic diseases of the cardiovascular and cerebrovascular systems, as well as Alzheimer's disease pathology. -
COX Inhibitor
Pentagamavunon-1 (PGV-1) is a COX-2 inhibitor that modulates multiple molecular pathways to induce apoptosis. This Curcumin analog exhibits notable oral bioactivity and suppresses key angiogenic factors, including vascular endothelial growth factor (VEGF). Additionally, PGV-1 inhibits NF-κB activation, highlighting its potential in cancer research and therapeutic applications targeting inflammation and tumor progression. -
NF-κB Inhibitor
2′-Hydroxychalcone is a hydroxyl derivative of chalcones that primarily inhibits the NF-κB signaling pathway. It has demonstrated significant anticancer activity, inducing autophagy and apoptosis specifically in breast cancer cells. Additionally, 2′-Hydroxychalcone exhibits enhanced antifungal properties against Paracoccidioides spp., making it a valuable reagent for cancer and fungal research applications. -
NF-κB Inhibitor/Nrf2/AMPK Activator
Panduratin A is a potent inhibitor of the NF-κB signaling pathway, recognized for its significant anti-inflammatory and antioxidant properties. It demonstrates protective effects against nephrotoxicity induced by Colistin, primarily by mitigating oxidative stress and enhancing mitochondrial function. Additionally, Panduratin A activates autophagy through an AMPK-dependent mechanism and exhibits potential anti-tuberculosis and antiviral activities by inhibiting the methyltransferase of SARS-CoV-2. These diverse biological activities make Panduratin A a valuable tool in various areas of research, including inflammation, cellular stress responses, and infectious diseases. -
IRAK4 Inhibitor
Emavusertib hydrochloride is an orally active inhibitor targeting IRAK4, with an IC50 of 57 nM, and FLT3. This compound effectively inhibits NF-κB and MyD88 signaling pathways, resulting in decreased production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, as it promotes apoptosis in cancer cells and demonstrates antitumor efficacy in mouse model studies. -
TRIP13 Inhibitor
DCZ0415 is a potent inhibitor of TRIP13, interfering with the nonhomologous end joining DNA repair mechanism and inhibiting NF-κB activity. This compound exhibits significant anti-myeloma activity in vitro, in vivo, and in primary cells obtained from drug-resistant myeloma patients, making it a valuable tool for research into therapeutic strategies against multiple myeloma. Its mechanism of action offers insights into the role of TRIP13 in cancer biology and the potential for targeted therapies. -
TLR2/4 Inhibitor
Robinin is a flavonoid that acts as an inhibitor of Toll-like receptors 2 and 4 (TLR2/4), modulating the TGF-β, TLR4/NF-κB, and TLR2-PI3k-AKT signaling pathways. This compound demonstrates significant anti-inflammatory and anti-tumor properties. Additionally, Robinin has been shown to enhance the anti-inflammatory effects of Methotrexate in experimental arthritis models and may mitigate cardiac toxicity induced by Doxorubicin. These attributes make Robinin a valuable reagent for research applications in inflammation and cancer therapy. -
ACE/IKK-β/PKC Inhibitor
Plantainoside D is a phenylethanoid glycoside that functions primarily as an inhibitor of IKK-β, with additional inhibitory effects on angiotensin-converting enzyme (ACE) and protein kinase C (PKC). It exhibits significant biological activities, including the reduction of glutamate release in the rat cerebral cortex, alleviating cell apoptosis through the inhibition of reactive oxygen species (ROS) and NF-κB activation. Additionally, Plantainoside D has been shown to improve outcomes in acute lung injury induced by sepsis via modulation of the Sirt3/NLRP3 signaling pathway. This compound is applicable in studies of neuroprotection, antioxidant activity, anti-inflammatory responses, and antihypertensive effects. -
TREM-1 Inhibitor
Nangibotide is a synthetic peptide that serves as a TREM-1 receptor inhibitor. By inhibiting NF-κB and NLRP3 inflammasome activation, Nangibotide effectively reduces the release of pro-inflammatory cytokines such as IL-1β and IL-8 and mitigates apoptosis. This reagent is valuable for research applications related to excessive inflammatory responses, including studies on myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure. Additionally, Nangibotide offers protective effects on tissues, such as the liver and lung, during inflammatory conditions. -
Prolyl-hydroxylase Inhibitor
Ethyl 3,4-dihydroxybenzoate is a competitive inhibitor of prolyl hydroxylase, effectively penetrating the blood-brain barrier. By inhibiting the hydroxylation of hypoxia-inducible factor (HIF), it stabilizes HIF-1α, thereby activating downstream pathways that promote autophagy and apoptosis in tumor cells. Additionally, it modulates inflammatory responses, inhibits the NF-κB pathway, enhances vascular permeability, and supports osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate is beneficial for research applications focused on cancer therapeutics, cardiovascular protection, bone metabolism regulation, and high-altitude cerebral edema management. -
Keap1-Nrf2 Protein-Protein Inhibitor
CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting an IC50 of 0.63 µM. This compound demonstrates significant anti-inflammatory and antioxidant properties by activating the Nrf2-dependent pathway and inhibiting the NF-κB-related inflammatory response. CPUY192018 is ideal for research applications focused on inflammation-related diseases and the modulation of oxidative stress. -
NF-κB Inhibitor
Dendrophenol is a potent NF-κB inhibitor known for its ability to suppress inflammatory responses. This compound exhibits significant cytotoxic effects against tumor cells, promoting cell cycle arrest and apoptosis, thereby demonstrating antitumor activity. Furthermore, Dendrophenol has been shown to inhibit vascular calcification through the suppression of WNT3/β-catenin activation, making it a valuable tool for research in cancer and vascular biology. -
NF-κB Expression Reducer, ERK 1/2 Activator, Beta-Adrenergic Receptor Modulator, Calcium Channel Inhibitor
Eupatorin is a flavonoid that functions primarily as an NF-κB expression reducer and an ERK 1/2 activator, while also modulating beta-adrenergic receptors and inhibiting calcium channels. It demonstrates significant antiproliferative and vasodilatory effects, inducing apoptosis and causing G2/M phase cell cycle arrest, alongside reactive oxygen species (ROS) production. Eupatorin has been shown to impact inflammatory mediators and calcium signaling pathways, making it relevant for research in breast cancer, hypertension, and leukemia. Metabolized by CYP1A1 and other CYP1 enzymes, Eupatorin yields bioactive metabolites that maintain antiproliferative properties. -
MALT1 Inhibitor
SGR-1505 is a small molecule inhibitor targeting MALT1, effectively modulating the NF-κB signaling pathway. This compound demonstrates significant anti-proliferative and antitumor activities by inhibiting MALT1 enzymatic activity, leading to alterations in cell cycle progression, DNA damage response, and apoptosis-related gene expression in in vivo tumor models. SGR-1505 exhibits both tumorostatic and regressive effects in activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) xenograft models. It is a valuable tool for research into activated B-cell-like diffuse large B-cell lymphoma, non-Hodgkin B-cell lymphomas, chronic lymphocytic leukemia, and mature B cell neoplasms. -
AKR1C1/JAK2/STAT3/NF-κB Inhibitor
Zingiberen Newsaponin is a potent inhibitor of the AKR1C1/JAK2/STAT3 and NF-κB signaling pathways. This steroid saponin compound demonstrates significant anti-hepatocellular carcinoma (HCC) activity by promoting cancer cell apoptosis through the induction of oxidative stress, as evidenced by the upregulation of ROS and MDA levels. Additionally, Zingiberen Newsaponin mitigates cerebral ischemia-reperfusion injury by reducing pro-inflammatory cytokines and enhancing superoxide dismutase (SOD) activity, thereby protecting neuronal cells. Furthermore, it has been shown to induce platelet aggregation, broadening its application in cardiovascular research. -
JAK2/STAT3/NF-κB Inhibitor
Reticuline acts as a JAK2/STAT3 and NF-κB signaling pathway inhibitor, displaying notable anti-inflammatory properties. It effectively downregulates the mRNA expression of pro-inflammatory cytokines such as TNF-α and IL-6 while also reducing the phosphorylation levels of JAK2 and STAT3. Additionally, Reticuline demonstrates potential cardiovascular effects, making it a valuable tool for research in inflammation and cardiovascular studies. -
JAK/STAT and NF-κB Inhibitor
JAK-IN-23 is a potent dual inhibitor of the JAK/STAT and NF-κB signaling pathways, targeting JAK1, JAK2, and JAK3 with IC50 values of 8.9 nM, 15 nM, and 46.2 nM, respectively. This compound effectively modulates the expression of interferon-stimulated genes (ISG) and inhibits NF-κB activation, exhibiting IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 demonstrates significant anti-inflammatory properties by reducing the release of various pro-inflammatory cytokines. Its applications include research into inflammatory bowel disease (IBD) and other related inflammatory conditions. -
IRAK4/IRAK1 Inhibitor
IRAK4 modulator-2 is a selective inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1, exhibiting IC50 values of 0.005 μM and 0.97 μM, respectively. This compound effectively disrupts IRAK-mediated signaling pathways, including JAK-STAT and NF-κB pathways, leading to a reduction in pro-inflammatory cytokine production, such as IL-1 and TNF. IRAK4 modulator-2 demonstrates potential for use in research focusing on autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. -
Cathepsin L/JAK Inhibitor
Dual Cathepsin L/JAK-IN-1 is a dual inhibitor targeting Cathepsin L (CTSL) and Janus kinases (JAK), exhibiting IC50 values of 0.68 μM for CTSL, 337.1 nM for JAK1, 5.251 nM for JAK2, 27.29 nM for JAK3, and 172.6 nM for TYK2. This compound effectively inhibits the activation of key signaling pathways, including MAPK, NF-κB, and JAK/STAT, thereby providing substantial anti-inflammatory effects. Dual Cathepsin L/JAK-IN-1 is useful for investigating mechanisms underlying acute lung injury (ALI) and other inflammatory conditions. -
IKKβ/JAK2 Inhibitor
EC-70124 is an orally active multikinase inhibitor that targets IKKβ and JAK2. By blocking IkB phosphorylation and the activation of STAT3 (Tyr705), EC-70124 inhibits NF-κB nuclear translocation and impedes STAT3 transcriptional activity. This compound has demonstrated the ability to reduce tumor growth and diminish cancer stem cell populations in prostate cancer cells and xenograft models, making it a valuable tool for research in prostate cancer. -
S100P Inhibitor
5-Methyl cromolyn disodium is a selective inhibitor of the S100P protein, targeting its interaction with the receptor for advanced glycation end-products (RAGE). It effectively suppresses NF-κB activity and cell proliferation while enhancing Gemcitabine-induced apoptosis. In preclinical mouse models, 5-Methyl cromolyn disodium demonstrates significant anti-tumor effects by reducing growth and metastasis of pancreatic ductal adenocarcinoma (PDAC), ultimately extending survival. This compound serves as a valuable tool for investigating pancreatic cancer mechanisms and potential therapeutic approaches. -
NF-κB Inhibitor
NF-κB-IN-5 is a potent inhibitor of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) that acts by directly interacting with the NF-κB complex. This compound demonstrates significant antitumor activity across multiple human cancer cell lines, including HCT116, U87-MG, HepG2, BGC823, and PC9, with IC50 values ranging from 2.02 to 5.35 μM. NF-κB-IN-5 also promotes apoptosis in U87-MG cells and induces cell cycle arrest in the G0/G1 phase, positioning it as a valuable tool for cancer research and therapeutic development. -
c-Myc Inhibitor
EP12 is a selective c-Myc inhibitor that stabilizes c-Myc G-quadruplexes. This compound induces apoptosis and causes DNA damage in multiple myeloma cells, effectively inhibiting their growth. Additionally, EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway, highlighting its potential in cancer research and therapeutic applications. -
IRAK4 Inhibitor
Emavusertib phosphate is a potent inhibitor of IRAK4, exhibiting an IC50 of 57 nM. This compound effectively disrupts NF-κB and MyD88 signaling pathways, leading to a significant reduction in pro-inflammatory cytokines such as IL-6 and IL-10. Emavusertib phosphate demonstrates both anti-inflammatory and anti-proliferative effects on cancer cells, promoting apoptosis and showcasing antitumor activity in preclinical mouse models. Its applications extend to investigating inflammatory diseases and cancer therapies. -
IRAK4 Inhibitor
Emavusertib maleate is a potent inhibitor of IRAK4, demonstrating an IC50 of 57 nM, and FLT3. This orally bioavailable compound inhibits NF-κB and MyD88 signaling pathways, effectively reducing the production of pro-inflammatory cytokines such as IL-6 and IL-10. Its anti-inflammatory and anti-proliferative properties make it a valuable tool for cancer research, promoting apoptosis in cancer cells and demonstrating antitumor activity in preclinical mouse models. -
NF-κB Inhibitor
Amorfrutin A is an NF-κB inhibitor that inhibits TNF-α-induced IκBα degradation, p65 nuclear translocation, and DNA-binding activity of the NF-κB complex. This compound promotes apoptosis in HeLa cells by enhancing the proteolytic activities of caspase-3 and PARP. Its mechanism suggests potential research applications in studying inflammation, cancer biology, and cell death pathways. -
IRAK4 Inhibitor
Emavusertib tosylate is a potent inhibitor of IRAK4, displaying an IC50 of 57 nM. By targeting IRAK4 and FLT3, it effectively disrupts NF-κB and MyD88 signaling pathways, resulting in the reduction of pro-inflammatory cytokines such as IL-6 and IL-10. This compound demonstrates significant anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptotic mechanisms. Additionally, Emavusertib tosylate has shown noteworthy antitumor activity in preclinical mouse models, making it a valuable reagent for cancer research and inflammation studies. -
TAK1 Inhibitor
Triptriolide is a TAK1 inhibitor that plays a pivotal role in regulating apoptosis in mouse podocytes. It enhances cell survival and protects podocyte function by modulating the Bcl-2 family proteins and inhibiting Caspase-3 activity. Additionally, Triptriolide activates the TAK1-NF-κB signaling pathway, leading to the upregulation of podocin. This reagent is relevant for studies focusing on kidney health and podocyte resilience under stress conditions. -
IRAK4 Inhibitor
Emavusertib mesylate is a potent inhibitor of IRAK4, demonstrating an IC50 of 57 nM. This orally active compound effectively disrupts the NF-κB and MyD88 signaling pathways, leading to a reduction in pro-inflammatory cytokines such as IL-6 and IL-10. Emavusertib mesylate displays anti-inflammatory and anti-proliferative properties against cancer cells, promoting apoptosis. Additionally, it has shown significant antitumor activity in mouse models, making it valuable for cancer research and therapeutic studies targeting inflammatory pathways. -
NF-κB/MAPK/FAK/Akt Inhibitor
Ephemeranthol A is an inhibitor of NF-κB, MAPK, FAK, and Akt signaling pathways. This phenanthrene compound demonstrates notable anti-inflammatory effects through the inhibition of NF-κB and MAPK pathways in macrophages. Additionally, Ephemeranthol A induces apoptosis and inhibits metastasis in non-small cell lung cancer by suppressing FAK/Akt signaling and epithelial-mesenchymal transition (EMT) processes. It is applicable for research into acute and chronic inflammatory diseases as well as non-small cell lung cancer. -
NF-κB p65 Inhibitor, Apoptosis Inducer
N-Desmethyldauricine is an inhibitor of NF-κB p65 with significant apoptotic effects. It effectively reduces p65 protein expression, induces apoptosis, and arrests the cell cycle at the G0/G1 phase. Additionally, N-Desmethyldauricine attenuates intercellular adhesion and inhibits the growth of 3D spheroids derived from triple-negative breast cancer. This compound is useful for research involving triple-negative breast cancer dynamics and therapeutic strategies. -
NF-κB Inhibitor
15-Deoxy-Δ12,14-prostaglandin A1 is a potent inhibitor of NF-κB signaling, functioning through the modulation of inflammatory pathways. It has been shown to induce apoptosis and effectively inhibit TNF-α-induced upregulation of adhesion molecules on endothelial cells, thereby preventing monocyte arrest. This compound is valuable for research in inflammation, cardiovascular diseases, and apoptosis studies. -
NF-κB Inhibitor
Declopramide is a potent NF-κB inhibitor that exerts antitumor effects by inducing apoptosis in cancer cells. It has demonstrated efficacy in inhibiting the proliferation of HL60 and K562 cell lines, as well as reducing tumor growth in a mouse model of human brain astrocytoma (T24). Additionally, Declopramide functions as a chemosensitizer, making it a valuable tool for investigating therapeutic strategies in cancer research.
